These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 5004603)

  • 21. [The secondary sensitivity of mycobacteria].
    Hejný J; Hejná A
    Z Tuberk Erkr Thoraxorg; 1967; 126(5):303-5. PubMed ID: 4299812
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
    Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mycobacterium tuberculosis resistance to antitubercular agents in Antananarivo in 2000].
    Ratsirahonana O; Rasolofo Razanamparany V; Rasolonavalona T; Rakotonirina V; Rakotoarisaonina A; Rakotoherisoa A; Ralamboson M; Cauchoix B; Rakotondramarina D; Ramarokoto H
    Arch Inst Pasteur Madagascar; 2002; 68(1-2):44-7. PubMed ID: 12643091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mode of action of antituberculous agents and ultrastructure of mycobacteria.
    Oka S; Yamaguchi J; Ariji F; Madokoro K; Kumano N
    Sci Rep Res Inst Tohoku Univ Med; 1971 Jul; 18(1):7-13. PubMed ID: 5005200
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.
    Toungoussova S; Caugant DA; Sandven P; Mariandyshev AO; Bjune G
    Int J Tuberc Lung Dis; 2002 May; 6(5):406-14. PubMed ID: 12019916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-course treatment regimens for patients with tuberculosis.
    Dutt AK; Stead WW
    Arch Intern Med; 1980 Jun; 140(6):827-9. PubMed ID: 6770770
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002).
    Negi SS; Gupta S; Lal S
    J Commun Dis; 2003 Jun; 35(2):74-81. PubMed ID: 15562952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Discrepancy between drug resistance of mycobacterium tuberculosis determined in vitro and in vivo].
    Belogurova VP; Gorislavets II; Ivanitskaia NN
    Probl Tuberk; 1971; 49(6):76-80. PubMed ID: 5000746
    [No Abstract]   [Full Text] [Related]  

  • 29. Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001.
    Vásquez-Campos L; Asencios-Solis L; Leo-Hurtado E; Quispe-Torres N; Salazar-Lindo E; Bayona J; Becerra MC
    Int J Tuberc Lung Dis; 2004 Apr; 8(4):465-72. PubMed ID: 15141740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comments on the current state of experimental chemotherapy of tuberculosis].
    Urbancík R; Markovic J
    Z Tuberk Erkr Thoraxorg; 1967; 126(3):169-73. PubMed ID: 4971152
    [No Abstract]   [Full Text] [Related]  

  • 31. [Combined chemotherapy of patients with tuberculosis - new regimens and dosage forms].
    Sokolova GB; Koriakin VA; Khalbaeva IV; Elistratova NA; Ziia AV
    Probl Tuberk; 1993; (5):21-3. PubMed ID: 8295879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Resistance of the Koch bacillus to antibacillary agents in the Department of the Lower Rhine].
    Cooreman J; Burghard G; Grosset J
    Rev Fr Mal Respir; 1983; 11(5):699-704. PubMed ID: 6419307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experimental therapy with so-called "minor" tuberculostatics].
    Freerksen E
    Wien Med Wochenschr; 1966 Oct; 116(42):874-7. PubMed ID: 6005730
    [No Abstract]   [Full Text] [Related]  

  • 35. Molecular determinants of drug resistance in tuberculosis.
    Riska PF; Jacobs WR; Alland D
    Int J Tuberc Lung Dis; 2000 Feb; 4(2 Suppl 1):S4-10. PubMed ID: 10688142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies of antituberculosis chemotherapy with an in vitro model of human tuberculosis.
    Crowle AJ
    Semin Respir Infect; 1986 Dec; 1(4):262-4. PubMed ID: 3120268
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experimental tuberculosis in mice, a model for the study of antitubercular chemotherapy].
    Rist N
    Arch Roum Pathol Exp Microbiol; 1971 Jun; 30(2):295-6. PubMed ID: 5004388
    [No Abstract]   [Full Text] [Related]  

  • 38. Respiratory pharmacology. Antituberculosis drugs.
    Davidson PT; Hanh LQ
    Clin Chest Med; 1986 Sep; 7(3):425-38. PubMed ID: 3533401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

  • 40. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.